Alumis’ lupus drug heads to Phase III despite mid-stage miss

Phase 3envudeucitinibNeutral

AI Analysis

Summary

Alumis is advancing envudeucitinib, an oral targeted therapy for systemic lupus erythematosus, to Phase III development despite missing mid-stage trial expectations. If approved, it could become one of the first oral targeted therapies for SLE on the market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase II trial did not meet expectations; program advancing to Phase III

Importance:5/10

Sentiment:

0.20

lupusSLEoral therapyPhase 3 advancementclinical development

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 2, 2026 10:03 AM

Read Original